Here are the 424B prospectus supplements from Quanome Technologies, Inc. (QNME) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow QNME and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNME filings page.
Quanome Technologies, Inc. (QNME) may issue and sell common stock through an at-the-market offering with an aggregate offering price of up to approximately $9,754,475. At the assumed price of $0.474 per share, the offering covers up to 20,579,061 shares; actual issuance will vary with sale prices. Maxim Group LLC may act as agent or principal and receive a commission of up to 3% of gross proceeds. Net proceeds are intended for working capital and general corporate purposes, business development and potential strategic transactions, including acquisitions; Quanome has no definitive acquisition plans for these proceeds.
Quanome had 34,427,559 shares outstanding as of October 20, 2026. It distributes pharmaceuticals in China and began AI compute-capacity and managed-inference activities through U.S. subsidiaries in September 2026; customer-service commencement remains subject to conditions. It has until January 4, 2027, in a second 180-calendar-day Nasdaq compliance period, to regain the $1.00 minimum bid price; the company stated it may effect a reverse split if necessary. PRC regulatory oversight and cross-border fund-transfer restrictions are disclosed risks.